Description
Dihexa Capsules | AT4/IRAP Inhibitor — Cognitive Research
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin IV analogue reported to be approximately 10 million times more potent than BDNF in synaptogenesis models. As an AT4/IRAP inhibitor, it potentiates HGF/MET signaling — a pathway involved in synapse formation and cognitive processing. This capsule format (10mg per capsule, 30 capsules) supports oral research protocols studying neuroplasticity and cognitive function.
Mechanism of Action
- AT4/IRAP inhibition — blocks insulin-regulated aminopeptidase, prolonging action of endogenous neuropeptides at synaptic sites
- HGF/MET potentiation — amplifies hepatocyte growth factor signaling through MET receptor, promoting dendritic spine formation
- Synaptogenesis — preclinical models show new synapse formation in hippocampal and cortical regions
- BDNF-independent pathway — acts through a mechanistically distinct route from classical neurotrophins
Research Areas
Dihexa is studied in models of cognitive impairment, neurodegeneration, hippocampal plasticity, and HGF/MET-related neuropathology. Research comparators include Semax (BDNF upregulation) and Selank (anxiolytic neuropeptide) for comprehensive cognitive research panels.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. J. Banks –
Dihexa capsules for our oral nootropic bioavailability research. Content purity confirmed >99% by our HPLC — matching the vial format quality. Capsule uniformity tested within spec. Excellent formulation.
E. Johanssen –
10mg Dihexa capsules — convenient for our oral HGF pathway research. Capsule content dissolved cleanly and showed expected synaptogenesis activity in our model. COA detailed. Fast delivery.
P. Abara –
Good Dihexa capsules. Content purity >98.5%. Weight uniformity within ±3%. COA thorough. Our oral cognitive enhancement model showed expected HGF receptor potentiation.